<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-24T07:23:47Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/395385" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/395385</identifier><datestamp>2026-01-15T01:42:57Z</datestamp><setSpec>com_1810_721</setSpec><setSpec>com_1810_256064</setSpec><setSpec>col_1810_218856</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>Self-assembly of a gonadotropin-releasing  hormone antagonist-Teverelix</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">https://doi.org/10.17863/CAM.124915</dc:identifier>
   <dc:creator>Li, Xinyang</dc:creator>
   <uketdterms:advisor>Jackson, Sophie</uketdterms:advisor>
   <dcterms:abstract>Peptide and protein aggregation (self-assembly) has been an important topic for many years, 
since it is implicated in a range of neurodegenerative diseases, such as Alzheimer’s, Parkinson’s 
and Huntington’s Diseases. At the same time, it also represents a significant challenge for the 
Pharmaceutical Industry, as many peptides and protein-based drugs have a propensity to self
assemble into amorphous or highly structured aggregates. Such processes can occur during the 
manufacture, purification, processing or even storage of therapeutic peptides, as they are 
exposed to different conditions (e.g., agitation and pH changes) which can enhance the intrinsic 
aggregation propensity. Aggregation is associated with a number of adverse effects, including 
loss of biological activity and gain of cytotoxicity and/or immunogenicity. Although most 
aggregation processes are deleterious, there are a few examples where self-assembly can be 
useful, for example, when the aggregates themselves can be used directly in drug delivery, as 
slow-release depots thus enhancing drug half-life in vivo.  In this work, the self-assembly of 
teverelix, a synthetic peptide which has been shown to be an effective treatment for prostate 
cancer, was studied. It was known that at high concentrations teverelix (in the form of a TFA 
salt) forms a microcrystalline suspension, which is compatible with subcutaneous injection, 
however, under other conditions it was known to form fibrillar structures. The mechanism of 
formation of either state, and the factors affecting the stability and rate of formation of these 
states was largely unknown.  
Since the behaviour of Tv at low and high concentrations is significantly different, the studies 
performed within this Thesis can be divided into two parts. First, low peptide concentrations 
(&lt; 10 mg/mL), were studied and fibrils found to be the main aggregated species. The amyloid 
identity of Tv fibrils was shown by X-ray fibre diffraction and some structural information on 
the Tv fibrils was extracted from the diffraction pattern. In parallel, the morphology and 
dimensions of the Tv fibrils were studied by transmission electron microscopy. The kinetics of 
fibril formation were investigated and factors including Tv concentration, pH, ionic strength 
and TFA concentration were demonstrated to have a considerable effect. Oligomeric species 
formed in freshly prepared solutions of Tv was studied by size-exclusion chromatography and 
Tv molecules found to be largely dimeric with some slightly larger oligomers also populated. 
By combining all the information obtained, a mechanism of Tv fibril formation is proposed. 
At high Tv concentrations (~75 mg/mL), microcrystals were found to the main species. The 
morphology and dimensions of the microcrystals was studied by transmission and scanning 
electron microscopy. All microcrystals had the rectangular-shaped morphology with the width 
varying from 500 nm to 2.5 m, length from 500 nm to 5 m. In addition, the stability of Tv 
microcrystals was studied using dilution experiments and the subsequent rapid formation of 
fibrils investigated. Considerable time and effort were put into determining the structure of Tv 
in its crystalline state.  Unfortunately, all the crystal screens and seeding experiments under a 
wide variety of conditions did not produce crystals of sufficient size/stability to solve the 
structure. One incomplete diffraction dataset was obtained but there was insufficient data for 
structure determination. 
Lastly, preliminary studies were performed on Tv-Ac samples at both low and high 
concentrations (1 mg/mL &amp; 75 mg/mL). At low concentration (pH 5.9-8.0), the behaviour of 
Tv-Ac is similar to Tv-TFA, and fibrils were the main aggregated species observed. A similar 
decrease in pH was observed after fibril formation by Tv-Ac and was attributed potentially to 
the deprotonation of the lysine side chain. At 75 mg/mL (pH 5.1), the behaviour of Tv-Ac was 
significantly different from Tv-TFA The cloudy microcrystalline suspension observed for Tv
TFA was not seen for Tv-Ac even when the pH value was adjusted to 2.0 similar to that of 75 
mg/mL Tv-TFA samples (pH was 1.74). Therefore, the TFA counterions play an important role 
in the formation of microcrystalline state of Tv.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2025-07-27</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>Doctor of Philosophy (PhD)</uketdterms:qualificationname>
   <dc:language>eng</dc:language>
   <uketdterms:sponsor>CSC Cambridge Scholarship</uketdterms:sponsor>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/395385</dcterms:isReferencedBy>
   <uketdterms:embargotype>controlled.access</uketdterms:embargotype>
   <dc:identifier xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/bitstreams/41561e23-c178-4e03-b1a8-41dd2e816fcf/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">9b20ba80adb68edeb5a6554a4e0ec2f4</uketdterms:checksum>
   <dcterms:license>https://www.repository.cam.ac.uk/bitstreams/fc5cda73-2c17-48b1-8c2f-e76873e2d6a5/download</dcterms:license>
   <uketdterms:checksum xsi:type="uketdterms:MD5">87eda9de84448d1f82354d60eee3eb5f</uketdterms:checksum>
   <dc:rights>http://purl.org/NET/rdflicense/allrightsreserved</dc:rights>
   <dc:subject>Amyloid fibril</dc:subject>
   <dc:subject>Kinetics of fibril growth</dc:subject>
   <dc:subject>Peptide crystals</dc:subject>
   <dc:subject>Theraputic peptide</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>